Generic Product News

Published Online: Monday, March 18, 2013
Follow Pharmacy_Times:

Finasteride Tablets
Marketed by: Dr. Reddy’s Laboratories
Compare to: Propecia (Merck & Co, Inc)
Indication: Finasteride Tablets are a bioequivalent generic version of Propecia. They are indicated for the treatment of male pattern hair loss in men only. They are not indicated for use in women. The recommended dose is 1 tablet once daily with or without meals. In general, daily use for 3 months or more is necessary before benefit is observed. Finasteride Tablets are available in bottle counts of 30 and 90.
Dosage Form: Tablets: 1 mg
For More Information: www.drreddys.com



Fenofibrate Tablets
Marketed by: Teva Pharmaceuticals
Compare To: TriCor (Abbott Laboratories)
Indication: Teva Pharmaceuticals offers fenofibrate tablets, the authorized generic version of Abbott Laboratories’ TriCor tablets. Fenofibrate tablets are indicated to decrease low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia. The tablets are also indicated for treatment of adult patients with severe hypertriglyceridemia. They may be taken without regard to meals.
Dosage Form: Tablets: 48 mg or 145 mg
For More Information: www.tevagenerics.com



Clindamycin in 5% Dextrose
Marketed by: Sandoz Inc
Compare to: Cleocin Phosphate in Dextrose 5% (Pfizer Inc)
Indication: Clindamycin in 5% dextrose is an antibiotic indicated for the treatment of serious infections caused by susceptible anaerobic bacteria. It is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. It should be reserved for use in penicillin-allergic patients or in patients for whom penicillin use is deemed inappropriate.
Dosage Form: Minibags: 300 mg/50 ml; 600 mg/50 ml; 900mg/50 ml
For More Information: www.us.sandoz.com



Clobetasol Emulsion Propionate Foam, 0.05%
Marketed by: Perrigo Company
Compare to: Olux-E Foam, 0.05% (GlaxoSmithKline)
Indication: Clobetasol emulsion propionate foam, 0.05% (emollient formulation) is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses of the scalp in patients 12 years or older. Patients should apply a thin layer of foam to the affected areas twice daily in the morning and evening for up to 2 weeks. Therapy should be discontinued once control has been achieved.
Dosage Form: Foam: 50 g; 100 g
For More Information: www.perrigo.com

Related Articles
The clinical risk calculators incorporated into dyslipidemia treatment guidelines may overestimate a patient’s risk of experiencing a cardiovascular event.
The FDA recently accepted for review New Drug Applications for Collegium Pharmaceuticals’ extended-release oxycodone formulation (Xtampza ER) and Pfizer’s extended-release oxycodone hydrochloride and naltrexone hydrochloride (ALO-02), a pair of opioid analgesics with abuse-deterrent properties.
Avella Specialty Pharmacy announced today that it has been selected by Pfizer as one of the limited groups of specialty pharmacies authorized to distribute the manufacturer’s breakthrough breast cancer drug—Ibrance (palbociclib)—which has just received fast-tracked approval from the FDA.
Read about the new OTC Products featured in February.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$